---
layout: post
title: "Finding Hope for Frizzle (FRRS1L) and Apertura Gene Therapy Announce License Agreement for the Development of a Gene Therapy Using TfR1 CapX, an AAV Capsid Designed to Target the Central Nervous System"
date: 2026-02-18T12:00:00+00:00
source: PR Newswire Releases
source_url: https://www.prnewswire.com/news-releases/finding-hope-for-frizzle-frrs1l-and-apertura-gene-therapy-announce-license-agreement-for-the-development-of-a-gene-therapy-using-tfr1-capx-an-aav-capsid-designed-to-target-the-central-nervous-system-302691466.html
significance: 7.00
---

<p>— Finding Hope for FRRS1L plans to initiate clinical trial using TfR1 CapX gene therapy in the second half of 2026, pending regulatory review — FORT COLLINS, Colo. and NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Finding Hope for Frizzle (FRRS1L), a parent-led nonprofit organization working to...</p>

**Source:** [PR Newswire Releases](https://www.prnewswire.com/news-releases/finding-hope-for-frizzle-frrs1l-and-apertura-gene-therapy-announce-license-agreement-for-the-development-of-a-gene-therapy-using-tfr1-capx-an-aav-capsid-designed-to-target-the-central-nervous-system-302691466.html)

**Published:** 2026-02-18 12:00:00 +0000

**Significance Score:** 7.00

[View original](https://www.prnewswire.com/news-releases/finding-hope-for-frizzle-frrs1l-and-apertura-gene-therapy-announce-license-agreement-for-the-development-of-a-gene-therapy-using-tfr1-capx-an-aav-capsid-designed-to-target-the-central-nervous-system-302691466.html)
